Cardiovascular Diseases Research in Nebraska
Cardiovascular Diseases Research (93.837) awarded $55.7 million to recipients in Nebraska in 47 grants from fiscal 2021 to 2025, 0.4% of the program's national total. Board of Regents of the University of Nebraska received the most, $45.0 million.
- Awarded in Nebraska$55.7 million
- Awards47
- Share of the program0.4%
- Rank among states33rd of 51
- National total$15 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 20 | $8.1 million |
| FY 2022 | 22 | $9.5 million |
| FY 2023 | 26 | $12.1 million |
| FY 2024 | 26 | $13.4 million |
| FY 2025 | 23 | $12.6 million |
Recipients in Nebraska
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| Board of Regents of the University of Nebraska | Colleges and universities | 36 | $45.0 million |
| University of Nebraska | Colleges and universities | 4 | $5.3 million |
| Board of Regents of the University of Nebraska | Colleges and universities | 5 | $4.4 million |
| Creighton University | Colleges and universities | 1 | $573,682 |
| University of Nebraska | Colleges and universities | 1 | $394,781 |
Open opportunities under this program
- Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
- Emerging Global Leader Award (K43 Independent Clinical Trial Required)
- NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
- NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
- NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
- Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
- NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
See all 82 on the program page
Questions people ask
How much Cardiovascular Diseases Research money goes to Nebraska?
$55.7 million from fiscal 2021 to 2025, across 47 awards. Nebraska ranks 33rd of 51 states and territories for this program.
Who receives Cardiovascular Diseases Research money in Nebraska?
The largest recipient is Board of Regents of the University of Nebraska, with $45.0 million in 36 awards. Next are University of Nebraska and Board of Regents of the University of Nebraska.
Can organizations in Nebraska apply now?
Yes, 82 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cardiovascular Diseases Research in other states
Other large programs in Nebraska
- Grants to States for Medicaid
- Highway Planning and Construction
- Education Stabilization Fund
- National School Lunch Program
- Disaster Grants - Public Assistance (Presidentially Declared Disasters)
- Child Care and Development Block Grant
- Children's Health Insurance Program
- Special Education Grants to States
- Broadband Equity, Access, and Deployment Program
- Greenhouse Gas Reduction Fund: Clean Communities Investment Accelerator